跳至主要内容
临床试验/EUCTR2019-001408-39-GB
EUCTR2019-001408-39-GB进行中(未招募)1 期

Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial - TAPERS

Cardiff University0 个研究点目标入组 40 人开始时间: 2020年2月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Within three years of diagnosis of a psychotic illness;
  • Aged 18-65.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Lacking capacity to consent to treatment and trial procedures (as assessed by the research nurse);
  • Acute psychotic episode at time of recruitment (PANSS rating >80 or who in the view of their treating team are too unwell to take part);
  • Currently prescribed antidepressant medication;
  • Contraindications to sertraline treatment e.g. concurrent contraindicated medications such as Monoamine Oxidase Inhibitors (MOAIs), pimozide or any other serotonergic drugs (e.g. triptans), or opiates;
  • Recurrent thrombotic illness;
  • Previous adverse reaction to sertraline;
  • Poorly controlled epilepsy;
  • Dependent on alcohol or other illicit substances (as per ICD11 definitions);
  • If psychosis is considered by the responsible clinician to be clearly substance induced AND there is evidence that the psychosis has resolved within one month of abstinence from the substance;
  • Any significant risk to themselves or others;
  • Confirmed pregnancy.

研究者

相似试验